Cardiovascular Complications by EGFR Tyrosine Kinase Inhibitors in Patients with Lung Cancer

Int Heart J. 2021;62(5):949-951. doi: 10.1536/ihj.21-507.

Authors

Koichi Kimura^{1

2}, Hiroyuki Morita²

Affiliations

¹ Department of Oncology and General Medicine, Division of Cardiology, The Institute of Medical Science, The University of Tokyo.
² Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.

PMID: 34588410
DOI: 10.1536/ihj.21-507

No abstract available

Publication types

Editorial

MeSH terms

Cardiovascular Diseases / chemically induced*
ErbB Receptors / antagonists & inhibitors
Humans
Lung Neoplasms / drug therapy*
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use

Substances

Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors